Juniper Biologics establishes global headquarters in Singapore

Juniper Biologics, a science-led specialty healthcare company focused on commercialising novel therapies, has established its Global Headquarters in Singapore. This announcement is supported by the Singapore Economic Development

Board (EDB) & the company is backed by

The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance. Juniper Biologics aims to build a patient-centric presence throughout key markets in Singapore & around the globe. The unit is set to carry out a full range of activities for its fast-growing international business for its portfolio of medicines in oncology & oncology supportive care, rare diseases & gene therapy, with a goal of expanding access of its pharmaceutical portfolio to patients across the emerging markets. The facility is furnished with active management & coordination around medical affairs, regulatory affairs, commercial & business development as well as all finance & invoicing activities.